Charles River Laboratories Price to Free Cash Flow Ratio 2011-2025 | CRL
Historical price to free cash flow ratio values for Charles River Laboratories (CRL) since 2011.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Charles River Laboratories Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2025-11-10 | 168.97 | 14.28 | |
| 2025-06-30 | 151.73 | $11.83 | 12.82 |
| 2025-03-31 | 150.52 | $11.29 | 13.33 |
| 2024-12-31 | 184.60 | $9.72 | 19.00 |
| 2024-09-30 | 196.97 | $10.89 | 18.09 |
| 2024-06-30 | 206.58 | $9.43 | 21.90 |
| 2024-03-31 | 270.95 | $8.03 | 33.74 |
| 2023-12-31 | 236.40 | $7.10 | 33.29 |
| 2023-09-30 | 195.98 | $7.16 | 27.39 |
| 2023-06-30 | 210.25 | $5.63 | 37.31 |
| 2023-03-31 | 201.82 | $5.37 | 37.61 |
| 2022-12-31 | 217.90 | $5.75 | 37.90 |
| 2022-09-30 | 196.80 | $5.47 | 36.00 |
| 2022-06-30 | 213.97 | $6.58 | 32.54 |
| 2022-03-31 | 283.97 | $7.99 | 35.53 |
| 2021-12-31 | 376.78 | $10.35 | 36.42 |
| 2021-09-30 | 412.67 | $8.80 | 46.90 |
| 2021-06-30 | 369.92 | $9.46 | 39.11 |
| 2021-03-31 | 289.83 | $9.43 | 30.72 |
| 2020-12-31 | 249.86 | $7.51 | 33.28 |
| 2020-09-30 | 226.45 | $8.85 | 25.58 |
| 2020-06-30 | 174.35 | $8.33 | 20.93 |
| 2020-03-31 | 126.21 | $7.75 | 16.29 |
| 2019-12-31 | 152.76 | $6.85 | 22.30 |
| 2019-09-30 | 132.37 | $5.98 | 22.13 |
| 2019-06-30 | 141.90 | $5.46 | 25.98 |
| 2019-03-31 | 145.25 | $5.44 | 26.69 |
| 2018-12-31 | 113.18 | $6.14 | 18.43 |
| 2018-09-30 | 134.54 | $6.62 | 20.32 |
| 2018-06-30 | 112.26 | $5.49 | 20.46 |
| 2018-03-31 | 106.74 | $5.14 | 20.77 |
| 2017-12-31 | 109.45 | $4.85 | 22.56 |
| 2017-09-30 | 108.02 | $4.84 | 22.34 |
| 2017-06-30 | 101.15 | $5.36 | 18.86 |
| 2017-03-31 | 89.95 | $5.04 | 17.85 |
| 2016-12-31 | 76.19 | $5.46 | 13.97 |
| 2016-09-30 | 83.34 | $5.43 | 15.35 |
| 2016-06-30 | 82.44 | $5.79 | 14.24 |
| 2016-03-31 | 75.94 | $5.89 | 12.89 |
| 2015-12-31 | 80.39 | $5.11 | 15.72 |
| 2015-09-30 | 63.52 | $4.69 | 13.55 |
| 2015-06-30 | 70.34 | $4.28 | 16.44 |
| 2015-03-31 | 79.29 | $3.76 | 21.10 |
| 2014-12-31 | 63.64 | $4.10 | 15.50 |
| 2014-09-30 | 59.74 | $3.61 | 16.54 |
| 2014-06-30 | 53.52 | $3.58 | 14.95 |
| 2014-03-31 | 60.34 | $3.38 | 17.87 |
| 2013-12-31 | 53.04 | $3.50 | 15.14 |
| 2013-09-30 | 46.26 | $3.53 | 13.09 |
| 2013-06-30 | 41.03 | $3.38 | 12.14 |
| 2013-03-31 | 44.27 | $3.57 | 12.39 |
| 2012-12-31 | 37.47 | $3.32 | 11.30 |
| 2012-09-30 | 39.60 | $3.12 | 12.71 |
| 2012-06-30 | 32.76 | $2.88 | 11.39 |
| 2012-03-31 | 36.09 | $3.03 | 11.89 |
| 2011-12-31 | 27.33 | $3.07 | 8.89 |
| 2011-09-30 | 28.62 | $3.06 | 9.34 |
| 2011-06-30 | 40.65 | $2.42 | 16.82 |
| 2011-03-31 | 38.38 | $1.99 | 19.30 |
| 2010-12-31 | 35.54 | $2.00 | 17.73 |
| 2010-09-30 | 33.15 | $1.85 | 17.95 |
| 2010-06-30 | 34.21 | $2.12 | 16.15 |
| 2010-03-31 | 39.31 | $2.16 | 18.18 |
| 2009-12-31 | 33.69 | $2.07 | 16.29 |
| 2009-09-30 | 36.98 | $1.91 | 19.40 |
| 2009-06-30 | 33.75 | $1.80 | 18.80 |
| 2009-03-31 | 27.21 | $1.46 | 18.58 |
| 2008-12-31 | 26.20 | $1.14 | 22.91 |
| 2008-09-30 | 55.53 | $1.04 | 53.27 |
| 2008-06-30 | 63.92 | $1.11 | 57.74 |
| 2008-03-31 | 58.94 | $0.74 | 79.22 |
| 2007-12-31 | 65.80 | $0.89 | 73.68 |
| 2007-09-30 | 56.15 | $0.36 | 154.09 |
| 2007-06-30 | 51.62 | $-0.04 | 0.00 |
| 2007-03-31 | 46.26 | $0.51 | 91.22 |
| 2006-12-31 | 43.25 | $-0.08 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $8.316B | $4.050B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $149.160B | 27.39 |
| HCA Healthcare (HCA) | United States | $104.809B | 17.35 |
| CVS Health (CVS) | United States | $98.432B | 11.32 |
| Cencora (COR) | United States | $70.698B | 22.81 |
| Elevance Health (ELV) | United States | $67.512B | 9.90 |
| Natera (NTRA) | United States | $28.518B | 0.00 |
| DiDi Global (DIDIY) | China | $26.027B | 21.27 |
| Labcorp Holdings (LH) | United States | $21.648B | 16.51 |
| Medpace Holdings (MEDP) | United States | $16.913B | 41.99 |
| BioMerieux (BMXMF) | France | $15.266B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.316B | 0.00 |
| ICON (ICLR) | Ireland | $12.734B | 12.64 |
| Solventum (SOLV) | United States | $12.452B | 12.09 |
| CochLear (CHEOY) | Australia | $12.172B | 0.00 |
| Viatris (VTRS) | United States | $11.714B | 4.36 |
| Revvity (RVTY) | United States | $10.462B | 19.26 |
| HealthEquity (HQY) | United States | $8.601B | 34.42 |
| Avantor (AVTR) | United States | $7.841B | 11.98 |
| Caris Life Sciences,�Inc (CAI) | United States | $6.997B | 0.00 |
| Sonic Healthcare (SKHHY) | Australia | $6.872B | 0.00 |
| BrightSpring Health Services (BTSG) | United States | $6.054B | 36.10 |
| Bausch + Lomb (BLCO) | Canada | $5.656B | 37.14 |
| Sotera Health (SHC) | United States | $4.472B | 21.56 |
| GeneDx Holdings (WGS) | United States | $4.122B | 72.40 |
| Amplifon S.p.A (AMFPF) | Italy | $4.059B | 23.68 |
| Alignment Healthcare (ALHC) | United States | $3.278B | 0.00 |
| Concentras Parent (CON) | United States | $2.469B | 15.41 |
| Premier (PINC) | United States | $2.325B | 22.54 |
| Surgery Partners (SGRY) | United States | $2.056B | 26.73 |
| Progyny (PGNY) | United States | $2.036B | 40.03 |
| Organon (OGN) | United States | $2.004B | 2.11 |
| Establishment Labs Holdings (ESTA) | $1.967B | 0.00 | |
| Ardent Health (ARDT) | United States | $1.955B | 7.55 |
| Pediatrix Medical (MD) | United States | $1.938B | 11.57 |
| PACS (PACS) | United States | $1.905B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.331B | 0.00 |
| Omada Health (OMDA) | $1.196B | 0.00 | |
| GoodRx Holdings (GDRX) | United States | $1.063B | 17.00 |
| CareDx (CDNA) | United States | $0.859B | 14.03 |
| Embecta (EMBC) | United States | $0.799B | 4.68 |
| InnovAge Holding (INNV) | United States | $0.685B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.668B | 9.20 |
| Nutex Health (NUTX) | United States | $0.660B | 10.00 |
| Sonida Senior Living (SNDA) | United States | $0.606B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.551B | 0.00 |
| Pomdoctor - (POM) | China | $0.544B | 0.00 |
| Charming Medical (MCTA) | $0.466B | 0.00 | |
| So-Young (SY) | China | $0.428B | 0.00 |
| CryoPort (CYRX) | United States | $0.428B | 0.00 |
| Enhabit (EHAB) | United States | $0.401B | 18.02 |
| Strata Critical Medical (SRTA) | United States | $0.396B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.385B | 5.78 |
| SBC Medicals (SBC) | United States | $0.355B | 7.77 |
| KindlyMD (NAKA) | United States | $0.325B | 0.00 |
| Oncology Institute (TOI) | United States | $0.310B | 0.00 |
| Agilon Health (AGL) | United States | $0.273B | 0.00 |
| LifeMD (LFMD) | United States | $0.243B | 0.00 |
| Shoulder Innovations (SI) | United States | $0.224B | 0.00 |
| Beauty Health (SKIN) | United States | $0.175B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.157B | 26.99 |
| Ascend Wellness Holdings (AAWH) | United States | $0.130B | 0.00 |
| DocGo (DCGO) | United States | $0.109B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.096B | 0.00 |
| Biodesix (BDSX) | United States | $0.060B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.050B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.035B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.027B | 0.00 |
| Synergy CHC (SNYR) | United States | $0.020B | 5.63 |
| Co-Diagnostics (CODX) | United States | $0.019B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.016B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.012B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.009B | 0.00 | |
| Intelligent Bio Solutions (INBS) | United States | $0.007B | 0.00 |
| ISpecimen (ISPC) | United States | $0.006B | 0.00 |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |